ArticleHaematologica2018
A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Design of a modified platelet immunofluorescence test to assess platelet-reactive antibody burden and its association with platelet functional exhaustion and clinical features in chronic immune thrombocytopenia.British journal of haematology · 2026Article
- Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness.Transfusion · 2026Article
- Immune-mediated platelet refractoriness: Mechanisms, diagnostics, and therapeutic breakthroughs.Transfusion medicine (Oxford, England) · 2026Review
- Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness.Haematologica · 2026Article
- The glycan fingerprint in immune thrombocytopenia.Research and practice in thrombosis and haemostasis · 2026Article
- Macrophages are key mediators of platelet refractoriness.Blood advances · 2026Article
- Targeting macrophages prevents alloantibody-mediated platelet clearance in a murine model of transfusion refractoriness.Blood advances · 2026Article
- Existence and significance of anti-HLA-C autoantibodies to primary and persistent platelet transfusion refractoriness in patients with hematologic disorders: a retrospective study from a single centre.Annals of medicine · 2025Article
- Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy.Blood advances · 2025Article
- Anti-HLA antibodies bound to monocytes altered antibody-mediated platelet phagocytosis and led to mild thrombocytopenia.Frontiers in immunology · 2025Article
- Laboratory diagnosis of heparin-induced thrombocytopenia: A retrospective experience.Journal of clinical laboratory analysis · 2023Article
- Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects.Frontiers in immunology · 2023Review
- Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusions.Journal of thrombosis and haemostasis : JTH · 2022Article
- Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets.Haematologica · 2022Article
- Article
- Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis.Frontiers in medicine · 2022Article
- The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies.International journal of molecular sciences · 2021Review
- An Optimized and Standardized Rapid Flow Cytometry Functional Method for Heparin-Induced Thrombocytopenia.Biomedicines · 2021Article
- Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia.Journal of clinical medicine · 2020Review
- Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets.Haematologica · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HLA antibodies are associated with refractoriness to platelet transfusion, leading to rapid platelet clearance, sometimes coinciding with clinical side effects such as fever and chills. The presence of HLA antibodies is not always manifested by clinical symptoms. It is currently unclear why refractoriness to platelet transfusion is only observed in a subset of patients. Here, we utilized the availability of a unique panel of human monoclonal antibodies to study whether these were capable of activating platelets. Three out of eight human HLA-specific monoclonal antibodies induced activation of HLA-matched platelets from healthy donors as evidenced by enhanced α-granule release, aggregation, and α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.